Cogent Biosciences, Inc.
COGT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $821,866 | $678,715 | $861,601 |
| - Cash | $125,297 | $127,598 | $126,003 | $98,165 |
| + Debt | $58,853 | $60,658 | $17,091 | $17,467 |
| Enterprise Value | – | $754,926 | $569,803 | $780,903 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$1,157 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$78,830 | -$72,058 | -$73,795 | -$72,626 |
| % Margin | – | – | – | – |
| Net Income | -$80,930 | -$73,529 | -$71,986 | -$67,927 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.71 | -0.64 | -0.52 | -0.61 |
| % Growth | -10.9% | -23.1% | 14.8% | – |
| Operating Cash Flow | -$64,286 | -$54,542 | -$66,511 | -$60,577 |
| Capital Expenditures | -$65 | -$131 | -$547 | -$75 |
| Free Cash Flow | -$64,351 | -$54,673 | -$67,058 | -$60,652 |